Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
303.3 EUR | +1.74% | +2.12% | -4.56% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 41.98 and 36.53 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.56% | 23.58B | - | ||
-4.72% | 182B | C+ | ||
-2.83% | 103B | C | ||
-5.01% | 66.94B | A | ||
+15.53% | 46.73B | B- | ||
-8.53% | 45.14B | B- | ||
+5.93% | 41.57B | B+ | ||
+17.67% | 30.48B | B | ||
+13.24% | 24.26B | A- | ||
-11.17% | 22.24B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- WST Stock
- WPS Stock
- Ratings West Pharmaceutical Services, Inc.